Lehman Brothers UK Capital Funding LP: Notice To The Holders Of The Preferred Securities


(MENAFN- GlobeNewsWire - Nasdaq) LONDON, Oct. 03, 2024 (GLOBE NEWSWIRE) --

NOTICE TO THE HOLDERS OF:

EUR 225,000,000 FIXED RATE TO CMS-LINKED GUARANTEED NON-VOTING, NON-CUMULATIVE PERPETUAL PREFERRED SECURITIES ("LP I Securities")

ISSUER: LEHMAN BROTHERS UK CAPITAL FUNDING LP ("LP I")

ISIN: XS0215349357

LIQUIDATION OF LB GP NO.1 LTD ("the Company") AND IMPLICATIONS FOR HOLDERS OF LP I SECURITIES

THIS NOTICE CONTAINS IMPORTANT INFORMATION THAT IS OF INTEREST TO THE REGISTERED AND BENEFICIAL OWNERS OF THE SUBJECT SECURITIES. IF APPLICABLE, ALL DEPOSITORIES, CUSTODIANS AND OTHER INTERMEDIARIES RECEIVING THIS NOTICE ARE REQUESTED TO EXPEDITE THE RE-TRANSMITTAL TO BENEFICIAL OWNERS OF THE SECURITIES IN A TIMELY MANNER.

Your attention is drawn to the formal notice contained in the PDF link below concerning the Company, LP I and the LP I Securities. In order to view the formal notice, it is recommended that you copy and paste the link into your browser.

If you have any difficulties in opening the link, please contact Samantha Hawkins at RSM UK Restructuring Advisory LLP by e-mail: ....

Dated: 3 October 2024

This notice is given by

Matthew Haw
RSM UK Restructuring Advisory LLP
as Joint Liquidator of LB GP No.1 Ltd

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ... or visit .


MENAFN03102024004107003653ID1108744110


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.